MedPacto, an innovative new drug development company, announced on November 5 that it participated in 'BIO Europe Fall 2025,' held in Vienna, Austria from November 3 to 5, where it conducted partnership discussions with global pharmaceutical companies.
President Woo Jeongwon and Kim Saerom, Head of MedPacto's US subsidiary, attended the event. MedPacto held pre-scheduled meetings with about 30 pharmaceutical and biotech companies from Europe and North America to discuss technology licensing and joint research for its oncology drug candidates, including 'Vactosertib' and 'MP010.'
According to MedPacto, participating companies showed significant interest in the global clinical trials for osteosarcoma patients using 'Vactosertib,' whose potential was recently confirmed, as well as in the results of ongoing clinical trials for colorectal and lung cancer.
MedPacto also shared updates on the preparation of the Investigational New Drug (IND) application for 'MP010,' which achieved complete remission (CR) in preclinical trials for pancreatic cancer and triple-negative breast cancer models, and received continued positive feedback from global pharmaceutical companies. MedPacto is currently pursuing early technology transfer for 'MP010.'
Woo Jeongwon, President of MedPacto, stated, "We had further in-depth discussions with companies we previously sought partnerships with at 'BIO USA' in June, and we hope to see tangible results such as technology transfer in the near future."
BIO Europe is the largest bio-partnering event in Europe, and this year, approximately 3,000 companies from about 60 countries participated, making it a great success.
MedPacto plans to present interim clinical results of 'Vactosertib' for osteosarcoma at the Society for Immunotherapy of Cancer (SITC 2025) Annual Meeting, which will be held in Maryland, USA from November 7 to 9.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
